The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients. J Respirol Indones [Internet]. 2022 Sep. 29 [cited 2025 Aug. 20];42(4):277–281. Available from: https://jurnalrespirologi.org/index.php/jri/article/view/370